Journals / Meandros Medical And Dental Journal / 2018 / Volume: 19 Issue: 1

Mycophenolate Mofetil Induced Remission in Steroid-Refractory Autoimmune Hemolytic Anemia

Emine Özdemir(PAMUKKALE ÜNİVERSİTESİ)
Yasemin Işık Balcı(PAMUKKALE UNIVERSITY)
Havva Evrengül(PAMUKKALE UNIVERSITY)
Gülay Sönmez(PAMUKKALE ÜNİVERSİTESİ)
Tuğçe Bozkurt(PAMUKKALE UNIVERSITY)
Eda Karadağlı(PAMUKKALE UNIVERSITY)
Aziz Polat(PAMUKKALE UNIVERSITY)
Pages
—
Publication Date
2018-04-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here, we present a patient, who is diagnosed with AIHA that we couldn’t manage remission by steroid treatment, and no response to rituxumab as an immunosuppressor, but treated successfully with microphenolat mofetil.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Autoimmune hemolytic anemia (AIHA) is a disease that is seen in 1/10.000 people and characterized by forming antibodies against red blood cells and degradation of these red blood cells in reticuloendothelial system.
📊
Key Findings & Data:Clinically normochrome and normocytic anemia, reticulocytosis, polychromasia in peripheral smear, spherocytes, indirect hyperbilirubinemia and increased lactate dehydrogenase are seen.
💡
Conclusion & Impact:Here, we present a patient, who is diagnosed with AIHA that we couldn’t manage remission by steroid treatment, and no response to rituxumab as an immunosuppressor, but treated successfully with microphenolat mofetil.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Steroid · autoimmune hemolytic anemia · mycophenolate mofetil

Abstract

Autoimmune hemolytic anemia (AIHA) is a disease that is seen in 1/10.000 people and characterized by forming antibodies against red blood cells and degradation of these red blood cells in reticuloendothelial system. Even autoimmune diseases can accompany, it is seen usually idiopathic. Paleness due to anemia, jaundice, tachycardia, darkening in urine color, hepatosplenomegaly are frequently seen clinical findings. Clinically normochrome and normocytic anemia, reticulocytosis, polychromasia in peripheral smear, spherocytes, indirect hyperbilirubinemia and increased lactate dehydrogenase are seen. Direct coombs test is the diagnostic test. Steroids are the first line drugs in treatment. The dosage and the treatment duration is formed according to patient’s clinical situation. The treatment is checked by complete blood count, reticulocyte and Coombs test. Immunosuppressor treatments are given to patients that don’t respond to treatment in 4-6 weeks or less patients who has recurrence at the time of decreasing the treatment dosage of corticosteroids. In few patient, that did not respond steroids, immunosuppressive treatments are used. Here, we present a patient, who is diagnosed with AIHA that we couldn’t manage remission by steroid treatment, and no response to rituxumab as an immunosuppressor, but treated successfully with microphenolat mofetil.

🔖

Cite This Article

Özdemir, E., Balcı, Y. I., Evrengül, H., Sönmez, G., Bozkurt, T., Karadağlı, E., Polat, A. (2018). Mycophenolate Mofetil Induced Remission in Steroid-Refractory Autoimmune Hemolytic Anemia. Meandros Medical And Dental Journal, Volume: 19 Issue: 1. https://doi.org/10.4274/meandros.1933

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Lanzkowsky P. Extracorpuscular Hemolytic Anemia. In: Lanzkowsky P. *Manual of Pediatric Hematology and Oncology*. 5th ed. USA: Elsevier, 2011: 247-56.
  2. Gehrs BC, Friedberg RC. Autoimmune Hemolytic Anemia. *American Journal of Hematology* 2002; 69: 258-71.
  3. Sève P, Bourdillon L, Sarrot-Reynauld F. Autoimmune hemolytic anemia and common variable immunodeficiency: a case-control study of 18 patients. *Medicine (Baltimore)* 2008; 87: 177.
  4. Aladjidi N, Leverger G, Leblanc T. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. *Haematologica* 2011; 96: 655.
  5. Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. *Blood* 1987; 69: 820.
  6. Garraty G. Immune hemolytic anemia associated with drug therapy. *Blood Rev* 2010; 24: 143-50.
  7. Collins PW, Newland AC. Treatment modalities of autoimmune blood disorders. *Semin Hematol* 1992; 29: 64-74.
  8. Gobert D, Bussel JB, Cunningham-Rundles C. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. *Br J Haematol* 2011; 155: 498-508.
  9. Zimmer-Molsberger B, Knauf W, Tiel E. Mycophenolate mofetil for severe autoimmune haemolytic anemia. *Lancet* 1997; 350: 1003-4.
  10. Zaja F, Iacona I, Masolini P. B cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. *Haematologica* 2002; 87: 189-95.
  11. Barros MMO, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. *Transfus Med Rev* 2010; 24: 195-21.